Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.
about
Targeted Therapies in Triple-Negative Breast CancerAtypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base.Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases.Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas.Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean PopulationClinical implications of molecular heterogeneity in triple negative breast cancer.Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 databaseComparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma.Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort.The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast CancerClinical management of breast cancer heterogeneity.Prognosis of Medullary Carcinoma of the Breast: 10 years' Experience in a Single Institution.Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.
P2860
Q26777736-5B652A92-1A99-4F45-8803-2EA7437B3B17Q31113537-99D86E32-29D8-4BF1-B71C-90A22068BABBQ31140585-796571E0-47D9-4D5A-AEF0-81449FFB89FAQ33769821-1A1738C2-32CD-405E-98A8-51E9926BBCEAQ33915057-BBCD1C80-0617-4CB5-8F4E-ADD44BEC328FQ34465749-EF83AD5E-01B8-4FC0-9C8A-B7EDC4F42A97Q34668723-B5BA5ECE-0343-414A-9664-49453C08D6D5Q35743495-0265D8DD-5164-40B5-899E-D52DB8AED8A2Q35840060-090E06CE-44A7-4B6A-AB4A-3C7F8A0D45FAQ36271396-46684774-D189-40B5-8F97-0FBE2A6F27E9Q37225635-AEDE030C-0215-4C9B-88CA-5E6C14E7B738Q37484662-3EF888A5-A78A-42E7-BBB7-613A8AD8B1C1Q37670725-9A8264E3-6C47-4447-881D-B93C07897472Q37720246-1498F7C9-D299-4ADB-8C78-5C495858718FQ38431284-7EFF6606-E857-4CF0-802E-8AECD3331B0DQ46838788-14F8C137-CD2A-4171-BD56-325CC1578FCCQ50075112-01C485C7-59F9-46EE-B842-55DF1E132F4AQ54212765-64CCC10F-4423-4E1F-BDA8-68F41A85B8D3
P2860
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Prognosis of medullary breast ...... er Study Group (IBCSG) trials.
@ast
Prognosis of medullary breast ...... er Study Group (IBCSG) trials.
@en
type
label
Prognosis of medullary breast ...... er Study Group (IBCSG) trials.
@ast
Prognosis of medullary breast ...... er Study Group (IBCSG) trials.
@en
prefLabel
Prognosis of medullary breast ...... er Study Group (IBCSG) trials.
@ast
Prognosis of medullary breast ...... er Study Group (IBCSG) trials.
@en
P2093
P2860
P356
P1433
P1476
Prognosis of medullary breast ...... er Study Group (IBCSG) trials.
@en
P2093
A Goldhirsch
A S Coates
B Thürlimann
C Öhlschlegel
R D Gelber
P2860
P304
P356
10.1093/ANNONC/MDS105
P577
2012-06-14T00:00:00Z